Regulus Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview

Regulus Therapeutics

06/11/2024 14:32

* Regulus Therapeutics Inc  RGLS.OQ   RGLS.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 7 (estimated) for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Regulus Therapeutics Inc
is
for a loss of 17 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Regulus
Therapeutics Inc is 7.50​, above​ its last closing price
of $1.49. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.16       -0.15      -0.17     Missed  -15.9
 Mar. 31 2024  -0.26       -0.22      -0.29     Missed  -30.3
 Dec. 31 2023  -0.40       -0.39      -0.40     Missed  -1.3​
 Sep. 30 2023  -0.41       -0.40      -0.40     Met     -0.8
 ​​Jun.        -0.41       -0.41      -0.37     Beat    9.8
 30 2023                                                
 Mar. 31 2023  -0.44       -0.44      -0.42     Beat    3.8​
 Jan. 1 0001               -0.51      -0.40     Beat    21.6
 Sep. 30 2022  -0.49       -0.49      -0.50     Missed  -2
 This summary was machine generated November 6 at 14:32 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)